

Selecting the Right Procedure in Glaucoma Surgery



A surgeon's perspective.

BY JOSÉ MARÍA MARTÍNEZ DE LA CASA, MD

Glaucoma management has evolved significantly, offering a variety of procedural interventions tailored to individual patient needs. The primary goal is to reduce IOP effectively while minimizing risks and preserving future treatment options. This requires a careful assessment of disease stage, patient life expectancy, and specific treatment goals.

KEY CONSIDERATIONS IN SELECTING A GLAUCOMA PROCEDURE

The Role of Clinical Evidence

Clinical evidence is paramount in guiding surgical decisions. Procedures supported by robust data provide confidence in their long-term safety and efficacy. The iStent® technologies, for instance, have over a million implantations worldwide and are backed by multiple randomized controlled trials.¹⁻⁴ Such extensive post-marketing surveillance is particularly reassuring for patients

in early disease stages who require sustained IOP control over time.

Benefits of Minimally Invasive Approaches

MIGS offer significant advantages, especially for patients with early or mild glaucoma. Procedures such as the iStent *inject*® W (Figure 1) trabecular microbypass achieve effective IOP reduction with minimal risk, presenting an overall safety profile similar to cataract surgery alone.¹ This low-impact approach results in low rates of postoperative inflammation¹ and preserves conjunctival tissue, which is crucial for maintaining future surgical options if the disease progresses.

WHY ISTENT INJECT® W IS AN OPTIMAL CHOICE

The iStent *inject*® W stands out due to several key characteristics and capabilities:

- **Effective IOP control.** As demonstrated in multiple randomized controlled trials, the iStent® technologies consistently help achieve target IOP

levels essential for slowing glaucoma progression.¹⁻⁵

- **Excellent safety profile.** When combined with cataract surgery, the iStent *inject*® W maintains an overall safety profile similar to cataract surgery alone, minimizing additional risk to the patient.¹
- **Efficacy across baseline IOP levels.** The iStent *inject*® W is effective regardless of preoperative IOP,⁴ making it versatile for a wide range of patients (Figure 2).
- **Enhanced quality of life.** Patients treated with the iStent *inject*® W experience reduced dependence on medications, leading to improved adherence and quality of life.²
- **Slowed visual field progression.** A recent meta-analysis indicates that early intervention with iStent® technologies can slow the progression of visual field loss.⁵ Moreover, the iStent *inject*® W is accessible to both cataract and glaucoma surgeons due to its short learning curve. Its minimally invasive



Figure 1. iStent *inject*® W, a truly microinvasive glaucoma technology.




Figure 2. iStent *inject*® W efficacy across baseline IOP levels.

